Uncontrolled activation of pro-inflammatory macrophages after myocardial infarction (MI)
accelerates adverse left ventricular (LV) remodeling and dysfunction. Hemin, an iron …

Reperfusion therapy is commonly applied after a myocardial infarction. Reperfusion,
however, causes secondary damage. An emerging approach for treatment of ischemia …

Induction of cardiac muscle regeneration following myocardial infarction (MI) represents a
major challenge in cardiovascular therapy, as the current clinical approaches are limited in …

Although ischemic heart disease is the leading cause of death worldwide, mainstay
treatments ultimately fail because they do not adequately address disease pathophysiology …

A challenge in treating cardiac injury is the low heart-specificity of the drugs. Nanostructured
lipid carriers (NLCs) are a relatively new format of lipid nanoparticles which have been used …

Although reperfusion is essential in restoring circulation to ischemic myocardium, it also
leads to irreversible events including reperfusion injury, decreased cardiac function and …

Macrophages are involved in every cardiovascular disease and are an attractive therapeutic
target. Macrophage activation is complex and can be either beneficial or deleterious …

Myocardial infarction (MI) induces a complex inflammatory immune response, followed by
the remodelling of the heart muscle and scar formation. The rapid regeneration of the blood …

Background After myocardial infarction (MI), inflammatory cells infiltrate the infarcted heart in
response to secreted stimuli. Monocytes are recruited to the infarct via CCR2 chemokine …

Acute myocardial infarction (MI) caused by ischemia and reperfusion (IR) is the most
common cause of cardiac dysfunction due to local cell death and a temporally regulated …